Dr. Dinner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
303 E Superior St
# Lurie
Chicago, IL 60611Phone+1 312-503-1761Fax+1 312-695-4300
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2010 - 2013
University of ChicagoResidency, Internal Medicine, 2007 - 2010
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2010 - Present
IL State Medical License 2013 - 2026
Clinical Trials
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
- Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 17
Publications & Presentations
PubMed
- 202 citationsAdolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.Peter F. Coccia, Alberto S. Pappo, Lynda K. Beaupin, Virginia F. Borges, Scott C. Borinstein
Journal of the National Comprehensive Cancer Network. 2018-01-01 - 94 citationsMyeloid growth factors, version 2.2017Jeffrey Crawford, Pamela S. Becker, James O. Armitage, Douglas W. Blayney, Julio C. Chavez
Journal of the National Comprehensive Cancer Network. 2017-12-01 - 70 citationsPretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell TransplantationAndrew S. Artz, Amittha Wickrema, Shira Dinner, Lucy A. Godley, Masha Kocherginsky
Biology of Blood and Marrow Transplantation. 2008-11-01
Abstracts/Posters
- Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in...Shira Dinner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Shira Dinner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...Shira Dinner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
